© 2022 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
The HCPLive ADHD condition center page is a comprehensive resource for clinical news and insights on ADHD. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for ADHD.
May 07, 2022
On the heels of the FDA approval of viloxazine extended-release capsules for adult ADHD, a neuropsychiatrist discusses the state of care and diagnosis among older patients.
May 01, 2022
The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.
April 26, 2022
Birgit H. Amann, MD; Rakesh Jain, MD, MPH; Theresa R. Cerulli, MD; and David W. Goodman, MD, share unmet needs and risks in the treatment of adult ADHD.
Dr David W. Goodman reviews the efficacy and tolerability of different classes of medications for the management of ADHD.
April 19, 2022
Rakesh Jain, MD, MPH, explores the role of an integrative treatment approach in regard to nonpharmacological treatment for the management of adult ADHD.
Rakesh Jain, MD, MPH, leads a discussion on factors that guide treatment selection for adult patients with ADHD.
April 13, 2022
The digital software program was significantly beneficial and tolerable among patients who used it over 6 weeks, according to new findings.
April 12, 2022
Experts in ADHD discuss the benefits and challenges of telehealth on the diagnosis and management of adult ADHD.
Birgit H. Amann, MD, and Greg Mattingly, MD, review patient and provider goals of treatment and provide insight on evaluating response to treatment for ADHD.
April 05, 2022
Greg Mattingly, MD; David W. Goodman, MD; Birgit H. Amann, MD; and Theresa R. Cerulli, MD, evaluate the role of pediatric ADHD guidelines and common misconceptions in the diagnosis and treatment of ADHD.
FDA Approves Baloxavir Marboxil to Treat, Prevent Flu in Younger At-Risk Children
COVID-19 Vaccination Rates Lower in Adults with Vision, Hearing Disabilities
Kidney-Urinary Tract Involvement with Intermediate Junctional Epidermolysis Bullosa